The primary objective of this study is:
• To determine the effects of ketamine, which blocks the ion-channel gated by the NMDA
receptor, on performance of cognitive tasks and the extent to which these effects can be
reversed by the dopamine receptor antagonist, risperidone.
The secondary objectives of this study are:
- To establish whether patients with schizophrenia are able to reliably complete the
biomarker test battery and to assess whether their responses are similar to healthy
volunteers treated with ketamine.
- To establish a multi-site recruitment and assessment capacity based on shared Standard
Operating Procedures across three study centres.
Phase:
Phase 4
Details
Lead Sponsor:
University of Manchester
Collaborators:
Cardiff University King's College London P1vital Limited